Paul Zerbinopoulos, OD
Optometrist · South Kingstown, RINPI 1154375418
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,047 of the $8,814 with a category attached, or 68.6%. 22 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 36.0% of the total. Among optometrist clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $64.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
- Bausch & Lomb Americas Inc.$894
- Alcon$782
- Glaukos Corporation$671
- Johnson & Johnson Vision Care, Inc.$586
- Tarsus Pharmaceuticals, Inc.$412
- plus $2K from 16 others
What the payments were for
- Consulting fees$2,40027%
- Speaking & faculty fees$3504%
- Travel & lodging$120%
- Food & beverage$6,04769%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $3,169 |
| Bausch & Lomb Americas Inc. | 22 | $894 |
| Alcon | 19 | $782 |
| Glaukos Corporation | 6 | $671 |
| Johnson & Johnson Vision Care, Inc. | 16 | $586 |
| Tarsus Pharmaceuticals, Inc. | 9 | $412 |
| Oyster Point Pharma, Inc. | 16 | $400 |
| Coopervision Inc. | 6 | $355 |
| AbbVie(2 entities) | 8 | $248 |
| Aerie Pharmaceuticals, Inc. | 2 | $248 |
| Dompe US, Inc. | 6 | $227 |
| Visionary Optics LLC | 1 | $180 |
| Biotissue Holdings Inc. | 7 | $163 |
| Novartis | 1 | $156 |
| Sight Sciences, Inc. | 1 | $147 |
| Akorn Operating Company LLC | 2 | $34 |
| Shire North American Group Inc | 1 | $32 |
| Kala Pharmaceuticals, Inc. | 2 | $29 |
| Rxsight Inc | 1 | $24 |
| Sun Pharmaceutical Industries Inc. | 1 | $24 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| ABB Con-cise Optical Group LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,814 in reported general payments places this provider in the 95th percentile of 226 optometrist providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 53 | $62,550 |
| LumiganBimatoprost | 115 | $43,132 |
| XiidraLifitegrast | 23 | $21,865 |
| TyrvayaVarenicline Tartrate | 23 | $19,346 |
| RocklatanNetarsudil Mesylat/Latanoprost | 45 | $17,963 |
| Cyclosporine | 25 | $9,820 |
| Alphagan PBrimonidine Tartrate | 34 | $9,394 |
| RhopressaNetarsudil Mesylate | 17 | $7,723 |
| Travoprost | 36 | $5,529 |
| Brimonidine Tartrate | 77 | $5,180 |
| Latanoprost | 318 | $4,395 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 102 | $3,688 |
| Brinzolamide | 20 | $3,319 |
| Fluorometholone | 44 | $3,317 |
| VyzultaLatanoprostene Bunod | 13 | $3,125 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $248 | $115,076202 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $248 | $25,68662 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $894 | $24,99036 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $400 | $19,34623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 optometrist providers in Rhode Island.
Other optometrist in South Kingstown
- Saad AhmedSouth Kingstown$3K
- Michael SaccucciSouth Kingstown$2K
- Kriti BhagatProvidence$343K
- Maria SampalisWarwick$135K
- Stephen MontaquilaWarwick$51K
- Matthew DoyleWarwick$9K
- Georgia PatsiopoulosWarwick$9K
- Lucia DangeloProvidence$6K
- Carl CorrowProvidence$5K
- John CorrowProvidence$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.